(19)
(11) EP 2 808 343 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.01.2020 Bulletin 2020/03

(45) Mention of the grant of the patent:
15.05.2019 Bulletin 2019/20

(21) Application number: 14171372.7

(22) Date of filing: 22.12.2008
(51) International Patent Classification (IPC): 
C07K 16/22(2006.01)
C07K 16/28(2006.01)
 C07K 16/24(2006.01)

(54)

Fc variants with altered binding to FcRn

Fc-Varianten mit veränderter Bindung zu FcRn

Variantes Fc avec liaison altérée en FcRn

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 26.12.2007 US 16793 P
25.02.2008 US 31353 P
18.04.2008 US 46353 P
02.05.2008 US 50172 P
10.07.2008 US 79779 P
22.09.2008 US 99178 P

(43) Date of publication of application:
03.12.2014 Bulletin 2014/49

(60) Divisional application:
19169906.5 / 3575317

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08866130.1 / 2235059

(73) Proprietor: Xencor, Inc.
Monrovia, CA 91016 (US)

(72) Inventors:
  • Chamberlain, Aaron
    San Diego, CA 92106 (US)
  • Dahiyat, Bassil
    Altadena, CA 91001 (US)
  • Desjarlais, John Rudolph
    Pasadena, CA 91104 (US)
  • Karki, Sher Bahadur
    Pomoa, CA 91767 (US)
  • Lazar, Gregory Alan
    Indianapolis, IN 46220 (US)

(74) Representative: HGF Limited 
Saviour House 9 St. Saviourgate
York YO1 8NQ
York YO1 8NQ (GB)


(56) References cited: : 
US-A1- 2006 173 170
   
  • DALL'ACQUA W F ET AL: "Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171-5180, XP002384463, ISSN: 0022-1767
  • SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 276, no. 9, 2 March 2001 (2001-03-02) , pages 6591-6604, XP002495886, ISSN: 0021-9258 [retrieved on 2000-11-28]
  • GHETIE V ET AL: "INCREASING THE SERUM PERSISTENCE OF AN IGG FRAGMENT BY RANDOM MUTAGENESIS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 15, no. 7, 1 January 1997 (1997-01-01), pages 637-640, XP000876642, ISSN: 1087-0156
  • HINTON PAUL R ET AL: "An engineered human IgG1 antibody with longer serum half-life", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 176, no. 1, 1 January 2006 (2006-01-01), pages 346-356, XP002482524, ISSN: 0022-1767
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).